Asset Details
Do you wish to reserve the book?
DNA Methylation as a Therapeutic Target for Bladder Cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
DNA Methylation as a Therapeutic Target for Bladder Cancer
Do you wish to request the book?
DNA Methylation as a Therapeutic Target for Bladder Cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
DNA Methylation as a Therapeutic Target for Bladder Cancer
2020
Overview
Bladder cancer (BC) is the tenth most frequent cancer worldwide and is associated with high mortality when diagnosed in its most aggressive form, which is not reverted by the current treatment options. Thus, the development of new therapeutic strategies, either alternative or complementary to the current ones, is of major importance. The disruption of normal epigenetic mechanisms, namely, DNA methylation, is a known early event in cancer development. Consequently, DNA methyltransferase (DNMT) inhibitors constitute a promising therapeutic target for the treatment of BC. Although these inhibitors, mainly nucleoside analogues such as 5-azacytidine (5-aza) and decitabine (DAC), cause re-expression of tumor suppressor genes, inhibition of tumor cell growth, and increased apoptosis in BC experimental models and clinical trials, they also show important drawbacks that prevent their use as a valuable option for the treatment of BC. However, their combination with chemotherapy and/or immune-checkpoint inhibitors could aid in their implementation in the clinical practice. Here, we provide a comprehensive review of the studies exploring the effects of DNA methylation inhibition using DNMTs inhibitors in BC, from in vitro and in vivo studies to clinical trials.
Publisher
MDPI AG,MDPI
Subject
/ Animals
/ Antimetabolites, Antineoplastic - pharmacology
/ Antimetabolites, Antineoplastic - therapeutic use
/ Azacitidine - therapeutic use
/ Cancer
/ Decitabine - therapeutic use
/ DNA
/ DNA Methylation - drug effects
/ Enzymes
/ Epigenesis, Genetic - drug effects
/ Genomes
/ Humans
/ Immune checkpoint inhibitors
/ Methods
/ Mutation
/ Patients
/ Review
/ therapy
/ Tumors
/ Urinary Bladder Neoplasms - drug therapy
/ Urinary Bladder Neoplasms - metabolism
/ Urine
